MDMA and 5‐HT neurotoxicity: the empirical evidence for its adverse effects in humans – no need for translation

• Published in: British journal of pharmacology Vol. 166; no. 5; pp. 1518 - 1520
• Main Author: Parrott, Andrew C
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-07-2012
• Subjects: 5‐HT neurotoxicity; Animals; Ecstasy; Hallucinogens - adverse effects; Humans; MDMA; Medical research; N-Methyl-3,4-methylenedioxyamphetamine - adverse effects; Neurotoxicity; Neurotoxicity Syndromes - etiology; Review with and Rebuttal; serotonin; SERT
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/j.1476-5381.2012.01941.x

In this issue of the BJP, Green et al. suggest that animal data could not be used to predict the adverse effects of 3,4‐methylenedioxymethamphetamine (MDMA) in humans and that MDMA did not produce 5‐HT neurotoxicity in the human brain. This proposal was, however, not accompanied by a review of the empirical evidence in humans. The neuroimaging data on 5‐HT markers in abstinent recreational ecstasy/MDMA users are extensive and broadly consistent. Reduced levels of the 5‐HT transporter (SERT) have been found by research groups worldwide using a variety of assessment measures. These SERT reductions occur across the higher brain regions and remain after controlling for potential confounds. There are also extensive empirical data for impairments in memory and higher cognition, with the neurocognitive deficits correlating with the extent of SERT loss. Hence, MDMA is clearly damaging to humans, with extensive empirical data for both structural and functional deficits.
LINKED ARTICLES This article is a commentary on Green et al., pp. 1523–1536 of this issue. To view this paper visit http://dx.doi.org/10.1111/j.1476‐5381.2011.01819.x. A rebuttal by Green et al. also appears in this issue, pp. 1521–1522. To view this rebuttal visit http://dx.doi.org/10.1111/j.1476‐5381.2012.01940.x